VistaGen Therapeutics, Inc. (VTGN)
VTGN Stock Price Chart
Explore VistaGen Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VTGN price movements and trends.
VTGN Company Profile
Discover essential business fundamentals and corporate details for VistaGen Therapeutics, Inc. (VTGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2011
Employees
48.00
Website
https://www.vistagen.comCEO
Shawn K. Singh
Description
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
VTGN Financial Timeline
Browse a chronological timeline of VistaGen Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.37, while revenue estimate is $500.00k.
Earnings released on 15 Jun 2026
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%, while revenue for the quarter reached $464.00k , beating expectations by +16.03%.
Earnings released on 12 Feb 2026
EPS came in at -$0.45 surpassing the estimated -$0.51 by +11.76%, while revenue for the quarter reached $303.00k , missing expectations by -16.86%.
Earnings released on 13 Nov 2025
EPS came in at -$0.54 falling short of the estimated -$0.51 by -5.88%, while revenue for the quarter reached $258.00k , beating expectations by +76.95%.
Earnings released on 7 Aug 2025
EPS came in at -$0.47 matching the estimated -$0.47, while revenue for the quarter reached $244.00k , beating expectations by +13.14%.
Earnings released on 17 Jun 2025
EPS came in at -$0.43 surpassing the estimated -$0.52 by +17.31%, while revenue for the quarter reached -$15.00k , missing expectations by -107.17%.
Earnings released on 13 Feb 2025
EPS came in at -$0.46 surpassing the estimated -$0.48 by +4.17%, while revenue for the quarter reached $234.00k , beating expectations by +28.57%.
Earnings released on 7 Nov 2024
EPS came in at -$0.42 falling short of the estimated -$0.40 by -5.00%, while revenue for the quarter reached $183.00k , missing expectations by -23.75%.
Earnings released on 13 Aug 2024
EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.63%, while revenue for the quarter reached $84.00k , missing expectations by -72.00%.
Earnings released on 11 Jun 2024
EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%, while revenue for the quarter reached $197.30k , missing expectations by -1.35%.
Earnings released on 13 Feb 2024
EPS came in at -$0.22 surpassing the estimated -$0.31 by +29.03%, while revenue for the quarter reached $411.40k , beating expectations by +105.70%.
Earnings released on 9 Nov 2023
EPS came in at -$0.66 surpassing the estimated -$0.68 by +2.94%, while revenue for the quarter reached $278.00k , beating expectations by +50.60%.
Earnings released on 10 Aug 2023
EPS came in at -$0.94 falling short of the estimated -$0.86 by -9.30%, while revenue for the quarter reached $177.00k , missing expectations by -1.67%.
Earnings released on 22 Jun 2023
EPS came in at -$1.75 falling short of the estimated -$1.50 by -16.67%, while revenue for the quarter reached $175.60k , missing expectations by -2.23%.
Stock split effective on 7 Jun 2023
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Feb 2023
EPS came in at -$1.50 surpassing the estimated -$1.80 by +16.67%, while revenue for the quarter reached $179.60k , beating expectations by +99.56%.
Earnings released on 10 Nov 2022
EPS came in at -$2.40 matching the estimated -$2.40, while revenue for the quarter reached -$892.50k , missing expectations by -387.86%.
Earnings released on 11 Aug 2022
EPS came in at -$3.00 falling short of the estimated -$2.70 by -11.11%, while revenue for the quarter reached $310.10k , beating expectations by +29.95%.
Earnings released on 23 Jun 2022
EPS came in at -$2.40 falling short of the estimated -$1.80 by -33.33%, while revenue for the quarter reached $38.90k , missing expectations by -88.51%.
Earnings released on 10 Feb 2022
EPS came in at -$1.50 surpassing the estimated -$2.40 by +37.50%, while revenue for the quarter reached $357.90k , beating expectations by +5.68%.
Earnings released on 10 Nov 2021
EPS came in at -$2.10 falling short of the estimated -$1.50 by -40.00%, while revenue for the quarter reached $358.00k , beating expectations by +1.01%.
Earnings released on 12 Aug 2021
EPS came in at -$1.20 surpassing the estimated -$1.50 by +20.00%, while revenue for the quarter reached $354.10k , beating expectations by +0.03%.
VTGN Stock Performance
Access detailed VTGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
